Valnoctamide
| Names | |
|---|---|
| Preferred IUPAC name
2-Ethyl-3-methylpentanamide | |
| Identifiers | |
3D model (JSmol) |
|
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.021.849 |
| EC Number |
|
| KEGG | |
| MeSH | valnoctamide |
PubChem CID |
|
| RTECS number |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C8H17NO | |
| Molar mass | 143.230 g·mol−1 |
| Appearance | White crystals |
| log P | 1.885 |
| Pharmacology | |
| N05CM13 (WHO) | |
| |
| Pharmacokinetics: | |
| 94% | |
| Hepatic | |
| 10 hours | |
| Hazards | |
| GHS labelling: | |
| Warning | |
| H302 | |
| Lethal dose or concentration (LD, LC): | |
LD50 (median dose) |
760 mg kg−1 (oral, rat) |
| Related compounds | |
Related alkanamides |
Valpromide |
Related compounds |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references | |
Valnoctamide (INN, USAN) has been used in France as a sedative-hypnotic since 1964. It is a structural isomer of valpromide, a valproic acid prodrug; unlike valpromide, however, valnoctamide is not transformed into its homologous acid, valnoctic acid, in vivo.